Blocking the Recruitment of Naive CD4 T Cells Reverses Immunosuppression in Breast Cancer
Overview
Authors
Affiliations
The origin of tumor-infiltrating Tregs, critical mediators of tumor immunosuppression, is unclear. Here, we show that tumor-infiltrating naive CD4 T cells and Tregs in human breast cancer have overlapping TCR repertoires, while hardly overlap with circulating Tregs, suggesting that intratumoral Tregs mainly develop from naive T cells in situ rather than from recruited Tregs. Furthermore, the abundance of naive CD4 T cells and Tregs is closely correlated, both indicating poor prognosis for breast cancer patients. Naive CD4 T cells adhere to tumor slices in proportion to the abundance of CCL18-producing macrophages. Moreover, adoptively transferred human naive CD4 T cells infiltrate human breast cancer orthotopic xenografts in a CCL18-dependent manner. In human breast cancer xenografts in humanized mice, blocking the recruitment of naive CD4 T cells into tumor by knocking down the expression of PITPNM3, a CCL18 receptor, significantly reduces intratumoral Tregs and inhibits tumor progression. These findings suggest that breast tumor-infiltrating Tregs arise from chemotaxis of circulating naive CD4 T cells that differentiate into Tregs in situ. Inhibiting naive CD4 T cell recruitment into tumors by interfering with PITPNM3 recognition of CCL18 may be an attractive strategy for anticancer immunotherapy.
Sex-related disparities in outcomes of survival in biliary tract cancer patients.
Sever N, Yunusov E, Majidova N, Kocaaslan E, Erel P, Agyol Y J Cancer Res Clin Oncol. 2025; 151(2):95.
PMID: 40016575 PMC: 11868355. DOI: 10.1007/s00432-025-06096-y.
Feng R, Li X, Li B, Luan T, He J, Liu G BMC Cancer. 2025; 25(1):317.
PMID: 39984869 PMC: 11843817. DOI: 10.1186/s12885-025-13731-x.
An Q, Duan L, Wang Y, Wang F, Liu X, Liu C J Transl Med. 2025; 23(1):179.
PMID: 39953548 PMC: 11829416. DOI: 10.1186/s12967-025-06167-1.
RNA methylation of CD47 mediates tumor immunosuppression in EGFR-TKI resistant NSCLC.
Zhang W, Wang J, Liang J, He Z, Wang K, Lin H Br J Cancer. 2025; .
PMID: 39900985 DOI: 10.1038/s41416-025-02945-2.
Nov P, Zhang Y, Wang D, Sou S, Touch S, Kouy S Ecancermedicalscience. 2025; 18():1794.
PMID: 39816386 PMC: 11735144. DOI: 10.3332/ecancer.2024.1794.